POINT Biopharma Reports First Quarter 2022 Financial Results and Provides Business Update

Posted: May 15, 2022 at 2:13 am

POINT's manufacturing facility initiated supply for the Phase 3 SPLASH trial. Randomization of patients for the SPLASH trial expanded to the European Union as scheduled.

Read the rest here:
POINT Biopharma Reports First Quarter 2022 Financial Results and Provides Business Update

Related Posts